Allakos Dirección
Dirección controles de criterios 3/4
El CEO de Allakos es Robert Alexander , nombrado en Apr 2017, tiene una permanencia de 7.58 años. compensación anual total es $6.30M, compuesta por 12.8% salario y 87.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.8% de las acciones de la empresa, por valor de $668.25K. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 6.4 años, respectivamente.
Información clave
Robert Alexander
Chief Executive Officer (CEO)
US$6.3m
Compensación total
| Porcentaje del salario del CEO | 12.8% |
| Permanencia del CEO | 7.6yrs |
| Participación del CEO | 0.8% |
| Permanencia media de la dirección | 3.6yrs |
| Promedio de permanencia en la Junta Directiva | 6.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Allakos Runs Up Into A Near-Term Catalyst
Nov 07We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully
Aug 27
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
May 05We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
Dec 01Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth
Aug 03Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Apr 20Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 04Allakos: Potential For Comeback With Lirentelimab With 2 Indications
Oct 18Allakos prices ~$150M underwritten offering
Sep 19Allakos falls as lead asset offers mixed results in late-stage trial
Sep 09Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Aug 06Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?
Apr 22Allakos: Sad End To A Promising Asset
Dec 23We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
Dec 01We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth
Aug 16Allakos: Upcoming Phase 3 Data Makes The Stock Interesting
Aug 06Allakos provides lirentelimab clinical trial enrollment updates, names new CMO
Jun 07We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
May 02Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?
Mar 10Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling
Jan 28
We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow
Dec 07Allakos EPS misses by $0.02
Nov 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$179m |
| Jun 30 2024 | n/a | n/a | -US$206m |
| Mar 31 2024 | n/a | n/a | -US$214m |
| Dec 31 2023 | US$6m | US$805k | -US$186m |
| Sep 30 2023 | n/a | n/a | -US$166m |
| Jun 30 2023 | n/a | n/a | -US$151m |
| Mar 31 2023 | n/a | n/a | -US$165m |
| Dec 31 2022 | US$7m | US$782k | -US$320m |
| Sep 30 2022 | n/a | n/a | -US$371m |
| Jun 30 2022 | n/a | n/a | -US$403m |
| Mar 31 2022 | n/a | n/a | -US$411m |
| Dec 31 2021 | US$11m | US$745k | -US$270m |
| Sep 30 2021 | n/a | n/a | -US$220m |
| Jun 30 2021 | n/a | n/a | -US$199m |
| Mar 31 2021 | n/a | n/a | -US$181m |
| Dec 31 2020 | US$14m | US$710k | -US$153m |
| Sep 30 2020 | n/a | n/a | -US$134m |
| Jun 30 2020 | n/a | n/a | -US$113m |
| Mar 31 2020 | n/a | n/a | -US$93m |
| Dec 31 2019 | US$13m | US$600k | -US$85m |
| Sep 30 2019 | n/a | n/a | -US$75m |
| Jun 30 2019 | n/a | n/a | -US$65m |
| Mar 31 2019 | n/a | n/a | -US$55m |
| Dec 31 2018 | US$8m | US$500k | -US$44m |
| Sep 30 2018 | n/a | n/a | -US$37m |
| Jun 30 2018 | n/a | n/a | -US$32m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$1m | US$300k | -US$24m |
Compensación vs. Mercado: La compensación total de Robert($USD6.30M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD652.28K).
Compensación vs. Ingresos: La compensación de Robert ha sido consistente con los resultados de la empresa en el último año.
CEO
Robert Alexander (54 yo)
7.6yrs
Permanencia
US$6,299,426
Compensación
Dr. Robert Alexander, Ph D., had been an Independent Director of Allena Pharmaceuticals, Inc. since June 2016 until 2022. He has been the Chief Executive Officer of Allakos Inc. since April 2017 and served...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 7.6yrs | US$6.30m | 0.80% $ 668.2k | |
| President | 5.3yrs | US$4.27m | 0.34% $ 289.0k | |
| Chief Financial Officer | 3.6yrs | US$2.74m | sin datos | |
| Chief Technical Officer | 1.3yrs | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | 0.32% $ 268.3k | |
| Director of Medical Affairs & Data Analytics | no data | sin datos | sin datos |
3.6yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ALLK se considera experimentado (3.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 7.5yrs | US$6.30m | 0.80% $ 668.2k | |
| Independent Director | 7yrs | US$387.12k | 0% $ 0 | |
| Independent Director | 8.6yrs | US$387.12k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$378.28k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$372.12k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$389.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 1.3yrs | US$732.48k | 0.043% $ 36.3k |
6.4yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de ALLK se considera experimentada (6.4 años de antigüedad promedio).